1417P - Prediction of long-term survival in metastatic gastrointestinal stromal tumour: analysis of a large, single-institution patient cohort

Date 10 October 2016
Event ESMO 2016 Congress
Session Poster display
Topics GIST
Presenter Ivar Hompland
Citation Annals of Oncology (2016) 27 (6): 483-492. 10.1093/annonc/mdw388
Authors I. Hompland1, Ø.S. Bruland1, J.P. Poulsen1, S. Stoldt2, T. Hølmebakk2, K.S. Hall1, K. Boye1
  • 1Department Of Oncology, Norwegian Radium Hospital, Oslo University Hospital, 0379 - Oslo/NO
  • 2Department Of Abdominal And Paediatric Surgery, Norwegian Radium Hospital, Oslo University Hospital, 0379 - Oslo/NO



Treatment of metastatic gastrointestinal stromal tumour (GIST) has improved considerably after the introduction of imatinib. A subset of patients become long-term survivors, and a more precise outcome prediction could improve clinical decision-making.


Patients diagnosed with metastatic GIST from 1995 to 2013 were identified from the sarcoma database at Oslo University Hospital. Clinical data were prospectively registered in the database and supplemented with retrospective review of medical records. Factors associated with survival were analysed using Kaplan-Meier curves, log-rank test and uni- and multivariate Cox regression analysis.


One-hundred thirty-three patients with metastatic GIST were identified, and 115 were included in the final study cohort. First-line treatment with imatinib was given to 111 patients, two received nilotinib and two never received systemic treatment. Second-line treatment was administered to 35 patients and third-line therapy to 19 patients. Median overall survival (OS) was 6.9 years (95 % Cl 5.6-8.3). After a median follow-up of 9.0 years 52 patients (43 %) were still alive. Factors associated with long-term survival in univariate analysis were good baseline performance status (ECOG ≤1; p 


In the present cohort oligometastatic disease and good performance status were the most important predictors of long-term survival. Patients with oligometastatic disease had an excellent outcome, and may be regarded as a separate category among patients with metastatic GIST.

Clinical trial identification

Legal entity responsible for the study



Rakel and Otto Kr Bruun's Legacy, Oslo University Hospital Foundation and the Norwegian Cancer Society


All authors have declared no conflicts of interest.